AC Immune Announces Results of Extraordinary Shareholders Meeting
May 02 2018 - 8:54AM
Lausanne, Switzerland, April 27, 2018 -
AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical stage
biopharmaceutical company focused on neurodegenerative diseases,
today announced that the shareholders of the Company have approved
all resolutions as proposed by the Board of Directors at the
Company's Extraordinary Shareholders' Meeting which took place
today in Lausanne, including:
- Election of Dr. Douglas Williams to the Board of Directors
- Election of Dr. Douglas Williams to the Compensation,
Nomination and Corporate Governance Committee
- Compensation for the newly elected Member of the Board of
Directors
- Authorization for future share capital increase
Martin Velasco, Chairman of the Board of
Directors, commented: "It is a pleasure to welcome Dr. Douglas
Williams to the Board of Directors. Mr. Williams has extensive
experience from corporate leadership and R&D roles over 30
years in the biotechnology industry and his appointment will bring
great benefit to AC Immune."
He added: "I want to thank our shareholders for
their continued trust and support. I am confident that AC Immune is
well positioned to become a global leader in precision medicine for
neurodegenerative diseases."
More information on the Extraordinary
Shareholders' Meeting is available on the Company's website.
About Dr. Douglas E. WilliamsDouglas E.
Williams, Ph.D., is currently the President, CEO and member of the
Board of Directors of Codiak BioSciences. He was previously
Biogen's Executive Vice President, Research and Development,
serving in this role from January 2011 to July 2015. He joined
Biogen from ZymoGenetics, where he was most recently CEO and member
of the Board of Directors. Previously, he held leadership positions
within the biotechnology industry, including Chief Scientific
Officer and Executive Vice President of Research and Development at
Seattle Genetics, and Senior Vice President and Washington Site
Leader at Amgen. Dr. Williams served in a series of scientific and
senior leadership positions over a decade at Immunex, including
Executive Vice President and Chief Technology Officer and a member
of the Board of Directors. During his 30+ year career in the
biotechnology industry he has played a role in the development of
several novel drugs including Enbrel, Tecfidera, and Spinraza. He
has served on the board of numerous biotechnology companies and is
currently a member of the Board of Directors of Ironwood
Pharmaceuticals, Ovid Pharmaceuticals, and AC Immune.
About AC ImmuneAC Immune is a clinical
stage Swiss-based biopharmaceutical company focused on
neurodegenerative diseases with five product candidates in clinical
trials. The Company designs, discovers and develops therapeutic and
diagnostic products intended to prevent and modify diseases caused
by misfolding proteins. AC Immune's two proprietary technology
platforms create antibodies, small molecules and vaccines designed
to address a broad spectrum of neurodegenerative indications, such
as Alzheimer's disease (AD). The Company's pipeline features nine
therapeutic and three diagnostic product candidates. The most
advanced of these is crenezumab, a humanized anti-amyloid-ß
monoclonal IgG4 antibody that targets monomeric and aggregated
forms of amyloid-ß, with highest affinity for neurotoxic oligomers.
Crenezumab is currently in Phase 3 clinical studies for AD, under a
global program conducted by the collaboration partner Genentech (a
member of the Roche group). Other collaborations include Biogen,
Janssen Pharmaceuticals, Nestlé Institute of Health Sciences,
Piramal Imaging and Essex Bio-Technology.
Forward looking statements This press
release contains statements that constitute "forward-looking
statements" within the meaning of Section 27A of the Securities Act
of 1933 and Section 21E of the Securities Exchange Act of 1934.
Forward-looking statements are statements other than historical
fact and may include statements that address future operating,
financial or business performance or AC Immune's strategies or
expectations. In some cases, you can identify these statements by
forward-looking words such as "may," "might," "will," "should,"
"expects," "plans," "anticipates," "believes," "estimates,"
"predicts," "projects," "potential," "outlook" or "continue," and
other comparable terminology. Forward-looking statements are based
on management's current expectations and beliefs and involve
significant risks and uncertainties that could cause actual
results, developments and business decisions to differ materially
from those contemplated by these statements. These risks and
uncertainties include those described under the captions "Item 3.
Key Information - Risk Factors" and "Item 5. Operating and
Financial Review and Prospects" in AC Immune's Annual Report on
Form 20-F and other filings with the Securities and Exchange
Commission. Forward-looking statements speak only as of the date
they are made, and AC Immune does not undertake any obligation to
update them in light of new information, future developments or
otherwise, except as may be required under applicable law. All
forward-looking statements are qualified in their entirety by this
cautionary statement.
For further information, please
contact:
In EuropeBeatrix BenzAC Immune Corporate Communications
Phone: +41 21 345 91 34E-mail: beatrix.benz@acimmune.com |
In the USLisa SherAC Immune Investor RelationsPhone: +1 970
987 26 54E-mail: lisa.sher@acimmune.com |
Nick Miles/Toomas KullCabinet Privé de Conseils s.a.Phone: +41 22
552 46 46 E-mail: miles@cpc-pr.comkull@cpc-pr.com |
Ted AgneThe Communications Strategy Group Inc.Phone: +1 781 631
3117E-mail: edagne@comstratgroup.com |
AC Immune (NASDAQ:ACIU)
Historical Stock Chart
From Aug 2024 to Sep 2024
AC Immune (NASDAQ:ACIU)
Historical Stock Chart
From Sep 2023 to Sep 2024